EU/3/17/1922:

Entospletinib

Overview

On 16 October 2017, orphan designation (EU/3/17/1922) was granted by the European Commission to Gilead Sciences International Ltd, United Kingdom, for entospletinib for the treatment of acute myeloid leukaemia.

The sponsorship was transferred to Rapport Global Strategic Services Ireland Limited, Ireland, in May 2021.

Key facts

Active substance
Entospletinib
Intented use
Treatment of acute myeloid leukaemia
Date of designation
16/10/2017
Orphan designation status
Positive
EU designation number
EU/3/17/1922

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Rapport Global Strategic Services Ireland Limited
22 Northumberland Road 
Ballsbridge
Dublin 4
Ireland
E-mail: support@rapportss.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating